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Heme (iron-protoporphyrin IX) is an essential co-factor involved in multiple biological
processes: oxygen transport and storage, electron transfer, drug and steroid metabolism,
signal transduction, and micro RNA processing. However, excess free-heme is highly
toxic due to its ability to promote oxidative stress and lipid peroxidation, thus leading
to membrane injury and, ultimately, apoptosis. Thus, heme metabolism needs to be
finely regulated. Intracellular heme amount is controlled at multiple levels: synthesis,
utilization by hemoproteins, degradation and both intracellular and intercellular trafficking.
This review focuses on recent findings highlighting the importance of controlling
intracellular heme levels to counteract heme-induced oxidative stress. The contributions of
heme scavenging from the extracellular environment, heme synthesis and incorporation
into hemoproteins, heme catabolism and heme transport in maintaining adequate
intracellular heme content are discussed. Particular attention is put on the recently
described mechanisms of heme trafficking through the plasma membrane mediated by
specific heme importers and exporters. Finally, the involvement of genes orchestrating
heme metabolism in several pathological conditions is illustrated and new therapeutic
approaches aimed at controlling heme metabolism are discussed.
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THE “GOOD” AND THE “BAD” FACE OF HEME
HEME AS A PROSTETIC GROUP IN HEMOPROTEINS
Heme is an iron-containing porphyrin of vital importance since
it constitutes the prosthetic moiety of several hemoproteins. It
can interact with different inactive apo-heme proteins giving
rise to active hemoproteins, whose function is ultimately deter-
mined by the properties of the polypeptide bound to it (Dawson,
1988). Thanks to its ability to coordinate an iron atom inside
its structure, heme is engaged in controlled oxido-reducing reac-
tions that allow hemoproteins to work properly. For this reason,
heme is involved in a multitude of crucial biological functions.
In hemoglobin and myoglobin, it is used for oxygen transport
and storage, respectively, whereas in cytochromes it is involved in
electron transport, energy generation, and chemical transforma-
tion. In catalases and peroxidases, heme functions in hydrogen
peroxide inactivation or activation, respectively, and in trypto-
phan pyrrolase, it catalyzes the oxidation of tryptophan (Kumar
and Bandyopadhyay, 2005). Furthermore, heme is indispensable
for a wide array of other important enzyme systems, such as
cyclooxygenase and nitric-oxide synthase (Seed and Willoughby,
1997).
HEME AS A MODULATOR OF GENE EXPRESSION AND CELL
PROLIFERATION/DIFFERENTIATION
Other than acting as a prostetic group in hemoproteins,
heme itself may influence the expression of many genes.
In non erythroid cells, heme regulates its own production
by down-regulating heme biosynthesis at the level of the
rate-limiting enzyme 5-aminolevulinic acid (ALA) synthase 1
(ALAS1) and by up-regulating its metabolism (Yamamoto et al.,
1982). Conversely, in erythroid cells, heme acts as a positive feed-
back regulator for its synthesis and inhibits its degradation (Sassa,
1976; Rutherford and Harrison, 1979). Heme may control gene
expression at almost all levels by regulating transcription, mRNA
stability, splicing, protein synthesis, and post-translational modi-
fication (Ponka, 1999; Zhu et al., 1999). Genes coding for globins,
heme biosynthetic enzymes, heme-oxygenase (HO)-1, ferro-
portin, cytochromes, myeloperoxidase, and transferrin receptor
are all regulated by heme. Most of these genes are regulated
via heme response elements (HREs) and the mammalian tran-
scription repressor, Bach1 (Ogawa et al., 2001). Heme respon-
sive elements (HREs) are located in enhancer regions of genes
induced by heme itself. The minimal heme response element was
identified as an extended activator protein 1 (AP-1, c-Fos/c-Jun
family) binding site, TGCTGAGTCAT/C. In addition to the
AP-1 heptad (TGAGTCA), this element also contains an inter-
digitated antioxidant response element (ARE), GCnnnGTCA.
This motif resembles the binding site of the transcription fac-
tors of the sMaf family (Maf recognition element, MARE; con-
sensus sequence: TGCTGAC(G)TCAGCA), which contains an
ARE core for transcription factors of the NF-E2 family (NF-
E2, Nrf1, Nrf2) (Inamdar et al., 1996). The transcription factor
Bach1 interacts with proteins of the Maf-related family and the
resulting heterodimer binds HRE elements, thus repressing gene
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transcription. Under conditions of intracellular heme accumu-
lation, heme binds to Bach1, thus leading to a conformational
change, a decrease in DNA binding activity and finally its removal
from HREs (Marro et al., 2010). This allows Maf-Maf, Nrf2-Maf,
and other activating heterodimers (Nrf2-AP-1) to occupy the
HRE sites in gene promoters and leads to increased transcription
of target genes.
In addition, heme regulates differentiation and proliferation of
various cell types. It stimulates neuronal differentiation of mouse
neuroblastoma cells (Ishii and Maniatis, 1978), erythroid dif-
ferentiation of erythroleukemia cells (Granick and Sassa, 1978),
formation of erythroid colonies in mouse as well as in human
bone marrow cultures (Partanen et al., 1988; Abraham et al.,
1991), differentiation of 3T3 fibroblasts into adipocytes (Chen
and London, 1981), and it stimulates cell growth of cultured
fibroblasts (Verger et al., 1983).
All together, these functions can be regarded as the “good face”
of heme, without which many critical biological processes would
not occur.
FREE HEME TOXICITY
In contrast to the positive functions of heme, free heme excess
can cause cell damage and tissue injury since heme catalyzes the
formation of reactive oxygen species (ROS), resulting in oxida-
tive stress. Heme that is not bound to proteins is considered the
labile heme pool; this portion of heme is derived from newly
synthesized heme that has not yet been incorporated into hemo-
proteins, or heme that has been released from hemoproteins
under oxidative conditions. “Free heme” is an abundant source
of redox-active iron that can participate in the Fenton reac-
tion to produce toxic free hydroxyl radicals. ROS damage lipid
membranes, proteins and nucleic acids, activate cell signaling
pathways and oxidant-sensitive, proinflammatory transcription
factors, alter protein expression, and perturb membrane chan-
nels (Vercellotti et al., 1994; Jeney et al., 2002). Heme toxicity is
further exacerbated by its ability to intercalate into lipid mem-
branes. Due to its lipophilic nature, heme may initially lodge
within the hydrophobic phospholipid bilayer. Within this highly
oxidizable matrix, iron catalyzes the oxidation of cell membrane
and promotes the formation of cytotoxic lipid peroxide, which
enhances membrane permeability, thus promoting cell lysis and
death (Balla et al., 1991; Ryter and Tyrrell, 2000; Kumar and
Bandyopadhyay, 2005; Tolosano et al., 2010). Additionally, heme
is a potent hemolytic agent. It affects erythrocyte membrane sta-
bility as a result of ROS formation and oxidative membrane dam-
age. Finally, heme is strongly pro-inflammatory since it induces
the recruitment of leukocytes, platelets and red blood cells to
the vascular endothelium, it oxidizes low-density lipoproteins
and it consumes nitric oxide, thus impairing vascular function
(Figure 1).
When intracellular heme accumulation occurs, heme is able to
exert its pro-oxidant and cytotoxic action. The cellular free heme
pool may increase after extracellular heme overload, increased
heme synthesis, accelerated hemoprotein breakdown, impaired
incorporation into apo-hemoproteins, or impaired HO activity,
resulting in ROS formation, oxidative damage and cell injury.
Several pathological conditions are associated with hemolysis
or myolysis, and tissues can subsequently be exposed to large
amounts of free heme (sickle cell anemia, thalassemia, malaria,
paroxysomal nocturnal hemoglobinuria, etc.) (Gozzelino et al.,
2010).
In summary, heme is a double-faced molecule: physiological
amounts of heme act in gene regulation or as the functional group
of hemoproteins, providing essential cellular functions, whereas
excessive free heme levels result in oxidative stress and tissue
injury. Therefore, the amount of free heme must be tightly con-
trolled to maintain cellular homeostasis and avoid pathological
conditions. To this purpose, mammals evolved several defense
mechanisms to specifically counteract free heme-mediated oxida-
tive stress and inflammation (Wagener et al., 2003; Gozzelino
et al., 2010).
Here the mechanisms involved in the maintenance of heme
homeostasis and in the control of heme levels are reviewed: the
regulation of both extracellular and intracellular heme content is
described, with particular emphasis on the emerging role of heme
transporters.
REGULATION OF EXTRACELLULAR HEME CONTENT
Mammals are equipped with various systems able to prevent
extracellular heme toxicity. Among them, a key function is cov-
ered by the soluble scavengers of free hemoglobin and heme,
Haptoglobin (Hp) (Schaer and Buehler, 2013; Schaer et al.,
2013a) and Hemopexin (Hx) (Tolosano et al., 2010), respectively.
During several pathological conditions, red blood cells
undergo hemolysis and hemoglobin and heme are released into
the circulation. Once released, free hemoglobin is captured by its
carrier Hp and transported to the macrophages of the reticulo-
endothelial system, where the complex is bound by the scavenger
receptor CD163. When the buffering capacity of plasma Hp is
exceeded, hemoglobin is quickly oxidized to methemoglobin,
which releases free heme (Ascenzi et al., 2005). Ferriheme is
then bound by Hx, by virtue of its high affinity (Figure 2). Hx
is a 57-kDa acute phase plasma glycoprotein able to bind an
equimolar amount of heme and to transport it into the circula-
tion. Hx is expressed mainly in the liver, but also in the brain
and retina (Tolosano et al., 1996, 2010). Hx is an acute phase
response protein. The acute phase response is a complex sys-
temic early-defence system activated by trauma, infection, stress,
neoplasia, and inflammation. Most of these stimuli, in particular
hemolytic stress and inflammatory stimuli, induce Hx synthesis
(Tolosano and Altruda, 2002). Hx functions as a heme scavenger,
maintaining lipophilic heme in a soluble state in aqueous envi-
ronment and is essential in the re-utilization of heme-bound iron
and prevention of heme-induced oxidative damage and cell death
(Eskew et al., 1999). Hx acts as an antioxidant thanks to the abil-
ity to tightly bind heme, thus effectively reducing heme toxicity
by 80–90% (Grinberg et al., 1999). Hx has the specific function
to deliver heme to hepatocytes where the heme-Hx complex is
internalized by receptor-mediated endocytosis. To date, the only
known Hx receptor is the LDL receptor-related protein 1 (LRP 1),
a multi-ligand scavenger receptor present on the surface of many
cell types. Some studies have suggested that Hx can be recy-
cled as an intact molecule to the extracellular milieu. However,
Hvidberg et al. have shown that most Hx is degraded in lysosomes
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FIGURE 1 | Free heme toxicity. Free heme has potentially toxic properties
due to the catalytic active iron atom it coordinates. Here, toxic effects of
heme are depicted. Heme causes cellular oxidative damage (1) by promoting
ROS formation, lipid peroxidation, DNA and protein damage. Additionally,
heme is a source of iron. Therefore, heme overload leads to intracellular
accumulation of iron, with further ROS generation. Heme is a hemolytic
agent (2), since it intercalates red blood cell membrane, thus favoring cell
rupture and further amplifying the hemolytic process. Heme promotes
inflammation (3), by stimulating inflammatory cell activation and cytokine
production. Finally, heme causes endothelial dysfunction (4) by several
mechanisms: increasing adhesion molecule expression and endothelial
activation, promoting inflammatory cell recruitment and platelet aggregation,
causing nitric oxide (NO) oxidative consumption and vasoconstriction,
oxidizing low-density lipoprotein (LDL).
(Hvidberg et al., 2005). The binding of Hx to free heme limits
the amounts of heme available as a catalyst of radical formation,
makes the essential iron unavailable to invasive microorganisms
and contributes to the recycling of iron, as heme iron enters the
intracellular iron pool.
Once the scavenging capacity of plasma Hx is exhausted,
free heme can still be scavenged by plasma albumin (∼66 kDa)
(Figure 2). Whether heme/albumin complexes are recognized by
specific receptors allowing heme degradation via the HO system
has not been established. Thus, the protective role of albumin
against heme toxicity remains uncertain (Tolosano et al., 2010).
REGULATION OF INTRACELLULAR HEME CONTENT
The control of intracellular heme content occurs at multiple
levels. Here we focus on the regulation of heme synthesis, degra-
dation and plasma membrane heme trafficking, which ensure
the maintenance of appropriate intracellular heme concentration.
Animal models discussed in this section are reported in Table 1.
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FIGURE 2 | Control steps in heme metabolism. The main mechanisms
involved in the control of heme levels outside, inside and across the cell
are illustrated. (1) Heme scavenging: Circulating free heme toxicity is
avoided thanks to the action of the scavenging proteins Hx and Albumin.
(2) Heme Import: Heme might be imported inside the cell via the
putative heme importers HCP1/PCFT and FLVCR2. (3) Heme Synthesis:
in the mitochondrion and cytosol, the heme biosynthetic enzymes,
starting from succinyl-CoA and glycine, give rise to heme. After
synthesis, heme is exported out of the mitochondrion to the cytosol by
the mitochondrial heme exporter FLVCR1b. (4) Heme Incorporation in
Hemoproteins: once released in the cytosol, heme is inserted in
apo-hemoproteins to allow the formation of functional hemoproteins.
(5) Heme Degradation: in the endoplasmic reticulum, the heme
degrading enzyme HO is responsible for heme degradation into iron (Fe),
carbon monoxide and biliverdin. (6) Heme Export: the heme exporters
FLVCR1a and ABCG2 regulate heme export out of the cell across the
plasma membrane. ALAS, aminolevulinic acid synthase; SLC25A38, solute
carrier family 25 member 38; ABCB10, ATP-binding cassette sub-family B
member 10; ALAD, amino levulinic acid dehydratase; HMBS,
hydroxymethylbilane synthase; UROS, uroporphyrinogen III synthase;
UROD, uroporphyrinogen decarboxylase; ABCB6, ATP-binding cassette
sub-family B member 6; CPOX, coproporphyrinogen oxidase; PPOX,
protoporphyrinogen oxidase; FECH, ferrochelatase; MFRN, mitoferrin;
FLVCR, feline leukemia virus subgroup C receptor; HCP1/PCFT heme
carrier protein 1/proton-coupled folate transporter; ABCG2, ATP-binding
cassette sub-family G member 2; HO, heme oxygenase; Hx, Hemopexin.
CONTROL OF HEME SYNTHESIS
The first level of regulation of cellular heme content occurs
at the level of heme synthesis control. Heme is synthesized
through a series of eight enzymatic reactions (Figure 2). Work
in the past decade has shown that heme synthesis is an
almost ubiquitous process. The biosynthesis of heme starts in
the mitochondrial matrix with the condensation of succinyl-
CoA and glycine to form ALA, a reaction catalyzed by the
enzyme ALAS. There are two isoforms of ALAS: Alas1 gene
is located on chromosome 3 in humans and codes for an
ubiquitously expressed protein whereas Alas2 gene is on the
X chromosome and codes for an erythroid-specific protein
(Bishop et al., 1990). The two isoforms of ALAS mainly
differ for their mode of regulation, as discussed later in this
section.
ALA is exported in the cytosol soon after its synthesis. The pre-
cise molecular mechanism by which ALA is transported through
the two mitochondrial membranes is not completely understood.
Two mitochondrial inner membrane proteins, SLC25A38 (solute
carrier family 25, member 38) and the ATP-binding cassette
transporter ABCB10 have been proposed to play this role.
Yeast lacking YDL119c, the ortholog of SLC25A38, shows a
defect in the biosynthesis of ALA (Guernsey et al., 2009). Thus, it
has been suggested that SLC25A38 could facilitate the production
of ALA by importing glycine into mitochondria or by exchang-
ing glycine for ALA across the mitochondrial inner membrane.
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Table 1 | Mouse models deficient for genes involved in the control of heme homeostasis.
Heme-related gene Mouse model Phenotype References
ALAS2 Alas2−/− mice Embryonic lethality; Impaired
erythropoiesis; iron accumulation in
primitive erythroid cells
Nakajima et al., 1999; Harigae
et al., 2003
HEMOPEXIN (Hx) Hx−/− mice Endothelial dysfunction, oxidative tissue
damage, iron tissue iron redistribution
following heme overload
Vinchi et al., 2008, 2013
HEME-OXYGENASE 1 (HO-1) Ho-1−/− mice Hepatic and renal iron loading; splenic
atrophy; macrophage depletion
Poss and Tonegawa, 1997;
Kovtunovych et al., 2010
FLVCR1 Flvcr1a/b−/− mice Embryonic lethality; Impaired
erythropoiesis; Reduced growth and
skeletal malformations
Keel et al., 2008
Flvcr1a/b−/− postnatal mice Macrocytic anemia Keel et al., 2008
Flvcr1a−/− mice Embryonic lethality; Hemorrhages, edema
and skeletal malformations
Chiabrando et al., 2012
Liver conditional Flvcr1a−/− mice
(Flvcr1aflox/flox;Alb-Cre)
Hepatic heme and iron loading; reduced
heme synthesis and cytochrome P450
expression/activity in hepatocytes
Vinchi et al., 2014
ABCG2 Abcg2−/− mice Photosensitization, PPIX accumulation Jonker et al., 2002
HCP1 Hcp1/PCFT −/− mice Mortality at 3 months; systemic and
cerebrospinal folate deficiency; severe
macrocytic normochromic anemia;
pancytopenia; liver iron accumulation
Salojin et al., 2011
Recently, Bayeva et al. reported that the silencing of ABCB10
causes a decrease of cellular and mitochondrial heme levels. The
administration of ALA fully restores heme level in ABCB10-
downregulated cells whereas Alas2 overexpression fails to do this.
Thus, it has been proposed that ABCB10 could facilitate mito-
chondrial ALA synthesis or its export frommitochondria (Bayeva
et al., 2013).
Both proteins are located on the inner mitochondrial mem-
brane; the ALA transporter on the outer mitochondrial mem-
brane still remains to be identified.
In the cytosol, two molecules of ALA are condensed to
form the monopyrrole porphobilinogen, a reaction catalyzed
by aminolevulinate dehydratase (ALAD). Then, the enzyme
hydroxymethylbilane synthase (HMBS) catalyzes the head-to-
tail synthesis of four porphobilinogen molecules to form the
linear tetrapyrrole hydroxymethylbilane which is converted to
uroporphyrinogen III by uroporphyrinogen synthase (UROS).
The last cytoplasmic step, the synthesis of coproporphyrinogen
III (CPgenIII), is catalyzed by uroporphyrinogen decarboxylase
(UROD) (Ajioka et al., 2006). All the remaining steps of heme
biosynthesis take place inside mitochondria, thus CPgenIII needs
to be transported in the mitochondrial intermembrane space. It
has been initially proposed that the ATP-binding cassette trans-
porter ABCB6 could play this role (Krishnamurthy et al., 2006).
However, data concerning the localization and function of ABCB6
in mitochondria are controversial. ABCB6 was also found to be
expressed on the plasma membrane, in the Golgi compartment
and in lysosomes. Some works even fail to detect ABCB6 in mito-
chondria (Paterson et al., 2007; Tsuchida et al., 2008; Kiss et al.,
2012). In addition, ABCB6 has been associated to other functions
unrelated to porphyrin homeostasis: ABCB6 contributes to anti-
cancer drug resistance (Kelter et al., 2007); it was identified as the
genetic basis of the Lan blood group antigen expressed on red
blood cells (Helias et al., 2012); defects in Abcb6 cause an inher-
ited developmental defect of the eye, with no known relationship
with porphyrins accumulation (Wang et al., 2012). Recently, it has
been reported that Abcb6−/− mice completely lackmitochondrial
ATP-driven import of CPgenIII and shows the up-regulation of
compensatory porphyrin and iron pathways. Abcb6−/− mice are
phenotypically normal; increased mortality and reduced heme
synthesis were observed following phenylhydrazine administra-
tion thus suggesting that Abcb6 is essential during conditions of
high porphyrin demand (Ulrich et al., 2012).
In the mitochondrial intermembrane space, CPgenIII is con-
verted to protoporphyrinogen IX by the enzyme copropor-
phyrinogen III oxidase (CPOX), a homodimer weakly associated
with the outside of the inner mitochondrial membrane. The fol-
lowing oxidation of protoporphyrinogen IX to protoporphyrin
IX (PPIX) is catalyzed by protoporphyrinogen oxidase (PPOX),
located on the outer surface of the inner mitochondrial mem-
brane. Finally, ferrous iron is incorporated into PPIX to form
heme in the mitochondrial matrix, a reaction catalyzed by the
enzyme ferrochelatase (FECH) (Ajioka et al., 2006). It has been
reported that FECH is part of a multi-enzyme complex composed
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by the mitochondrial iron importer MITOFERRIN1 (MFRN1)
and the ATP-binding cassette transporter ABCB10. The associa-
tion of FECH with MFRN1 allows the coupling of mitochondrial
iron import and the integration of iron into PPIX ring while
ABCB10 stabilizes MFRN1 expression (Chen et al., 2009, 2010).
Once synthesized, heme must be exported through the two
mitochondrial membranes for incorporation into hemoproteins.
The only mitochondrial heme exporter identified to date is the
mitochondrial isoform of Flvcr1 (Feline Leukemia Virus sub-
group C Receptor 1) gene. Two different isoforms of FLVCR1
exist, FLVCR1a and FLVCR1b, expressed on the plasma mem-
brane and mitochondria respectively. FLVCR1b derives from an
alternative transcription start site located in the first intron of
the Flvcr1 gene thus resulting in the production of a shorter
protein (Chiabrando et al., 2012). Flvcr1a transcript codes for
a protein with 12 transmembrane domains (Tailor et al., 1999;
Quigley et al., 2000) while Flvcr1b mRNA codes for a pro-
tein with just six transmembrane domains (Chiabrando et al.,
2012). The role of FLVCR1b as a mitochondrial heme exporter
is suggested by in vitro data indicating that its overexpression
promotes heme synthesis whereas its silencing causes detrimen-
tal heme accumulation in mitochondria. Moreover, FLVCR1b
expression is upregulated following the stimulation of heme syn-
thesis in vitro (Chiabrando et al., 2012). According to its role as
a mitochondrial heme exporter, FLVCR1b is essential for ery-
throid differentiation both in vitro and in vivo (as discussed in
section Control of Heme Export). The submitochondrial localiza-
tion of FLVCR1b is still unknown as well as its ability to interact
with other mitochondrial transporters. Further work is needed to
definitively understand how heme is transported across the two
mitochondrial membranes.
The importance of controlling the rate of heme synthesis is
highlighted by the fact that mutations in many genes coding for
enzymes involved in this pathway cause specific pathological con-
ditions characterized by the accumulation of toxic heme precur-
sors (as discussed in section Pathological Conditions Associated
with Alterations of Heme Synthesis). The regulation of heme
synthesis mainly occurs at the level of ALAS, the first and rate-
limiting enzyme of the heme biosynthetic pathway. It has been
demonstrated that heme plays an essential role in the regulation
of its own synthesis by regulating the expression of ALAS.
In non-erythroid cells, heme synthesis is dependent on the
activity of ALAS1. It has been reported that ALAS1 is directly
regulated by heme levels through several mechanisms: heme
negatively controls the transcription (Yamamoto et al., 1982),
translation (Sassa and Granick, 1970; Yamamoto et al., 1983) and
stability (Hamilton et al., 1991) ofAlas1mRNA. In addition, it has
been shown that ALAS1 contains three heme regulatory motifs
(HRMs). Heme binding to two of these HRMs, located in the
mitochondrial targeting sequence of ALAS1, inhibits the trans-
port of ALAS1 precursor protein in mitochondria (Yamauchi
et al., 1980). The regulation of ALAS1 by heme represents a
crucial negative feedback mechanism to maintain appropriate
intracellular heme levels in non-erythroid cells, thus avoiding
heme-induced oxidative damage.
In erythroid cells, heme synthesis is exclusively dependent on
the activity of ALAS2. Contrary to ALAS1, heme does not inhibit
the expression of ALAS2, as high amount of heme are required
for the differentiation of erythroid progenitors. The expression
of ALAS2 is controlled at multiple levels. The transcription of
Alas2 is regulated by erythroid-specific transcription factors, like
GATA1 (Surinya et al., 1998; Kaneko et al., 2013). At the post-
transcriptional level, the expression of ALAS2 is regulated by iron
availability. The 5′ untranslated region of Alas2 mRNA contains
an iron responsive element (IRE) which interacts with iron reg-
ulatory protein (IRP) 1 and 2. The IRE binding activity of IRPs
is regulated by cellular iron. In iron-deficient cells, the binding
of IRPs to the 5′IRE inhibits the translation of Alas2 mRNA. In
iron-repleted cells, IRPs are degraded thus stimulating the trans-
lation of Alas2 mRNA. This mechanism ensures the coordination
of heme synthesis to the availability of iron thus avoiding the pro-
duction of potentially toxic heme precursors when iron concen-
trations are limiting. The regulation of the IRE-binding activity
of IRPs by cellular iron occurs through several mechanisms. The
IRE binding activity of IRP1 is controlled by iron-sulfur clusters
assembly while that of IRP2 by its oxidation, ubiquitination and
degradation by the proteasome (Hentze et al., 2010). This lat-
ter process is dependent on iron but also on heme availability.
It has been reported that IRP2 contains a HRM; heme bind-
ing to the HRM mediates the oxidation of IRP2 that triggers its
ubiquitination and degradation (Yamanaka et al., 2003; Ishikawa
et al., 2005). Thus, during the differentiation of erythroid pro-
genitors, increased cellular iron level stimulates the translation of
Alas2 mRNA by inducing the degradation of IRPs. The following
accumulation of heme contributes to the oxidation and degra-
dation of IRP2, further enhancing heme synthesis. This positive
feedback mechanism allows a sustained production of heme for
hemoglobin synthesis in differentiating erythroid progenitors.
CONTROL OF HEME INCORPORATION INTO HEMOPROTEINS
The rate of de novo heme synthesis has to be proportionate to its
rate of incorporation into newly synthesized apo-hemoproteins.
This is obtained at different levels via the control of heme syn-
thesis as well as apo-hemoproteins synthesis. As reported in
section Heme as a Modulator of Gene Expression and Cell
Proliferation/Differentiation, heme itself can induce the tran-
scription and the expression of several apo-hemoproteins, such
as hemoglobin, myoglobin, and neuroglobin (Bruns and London,
1965; Tahara et al., 1978; Zhu et al., 1999, 2002; Correia et al.,
2011), as well as cytochromes and many other heme-containing
proteins. This evolutionary conserved strategy prevents intracel-
lular heme accumulation, presumably limiting heme cytotoxicity
(Figure 2). Additionally, in non-erythroid cells, heme is able
to regulate its own synthesis and degradation via inhibition
of ALAS1 expression/activity and induction of HO-1 expres-
sion/activity, thus properly balancing the amount of synthesized
heme with that one incorporated into hemoproteins or catabo-
lized (Zheng et al., 2008; Correia et al., 2011).
CONTROL OF HEME DEGRADATION
HO is the primary enzyme involved in heme degradation and
plays an important role in the protection of cells from heme-
induced oxidative stress. It is a 32 kDa protein, mainly located on
membranes of the smooth endoplasmic reticulum, able to break
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down the pro-oxidant heme into the antioxidant biliverdin, the
vasodilator carbon monoxide (CO) and iron (Fe2+) (Figure 2)
(Gozzelino et al., 2010; Tolosano et al., 2010). Biliverdin is then
reduced to bilirubin by the enzyme biliverdin reductase. To
date, three isoforms of HO have been identified: HO-1, HO-2,
and HO-3.
HO-1 is highly inducible by a variety of stimuli includ-
ing oxidative stress, heat shock, hypoxia, ischemia-reperfusion,
lipopolysaccharide, heavy metals, cytokines and its substrate
heme. Heme is the most potent physiologic inducer of HO-1. The
enzyme activity was shown to increase in many tissues, includ-
ing the liver, kidney, adrenals, ovaries, lung, skin, intestine, heart,
and peritoneal macrophages. HO-2 is ubiquitously expressed and
participates in the normal heme capturing and metabolism. The
isoenzymes HO-1 and HO-2 are products of two different genes.
The two forms show only 45% aminoacid homology but they
share a region with 100% secondary structure homology, that
corresponds to the catalytic site (Maines, 1988). HO-3 has poor
heme-degrading capacity (Wagener et al., 2003).
Herein, we focus on the inducible isoform HO-1.
HO-1 plays a vital function in heme degradation and pro-
tects against heme-mediated oxidative injury. Overexpression of
HO-1 is associated to the resolution of inflammation through the
generation of beneficial molecules like CO, bilirubin, and ferritin
resulting from catabolism of toxic heme (Wagener et al., 2001,
2003; Kapturczak et al., 2004). Bilirubin efficiently scavenges per-
oxyl radicals, thereby inhibiting lipid peroxidation, attenuating
heme-induced oxidative stress, cell activation and death (Dore
et al., 1999; Soares et al., 2004; Kawamura et al., 2005). CO
controls the activity of several heme proteins and causes vasodi-
lation. It also exerts anti-inflammatory effects by inhibiting the
expression of pro-inflammatory cytokines (Ndisang et al., 2003;
Beckman et al., 2009). Finally, ferritin, by sequestering toxic free
iron, limits microrganism growth and ROS production.
HO-1 confers cytoprotection against different forms of pro-
grammed cell death, including apoptosis driven by heme and
tumor necrosis factor (Gozzelino and Soares, 2011). This cyto-
protective effect is driven by heme degradation per se as well
as by its end products, CO and biliverdin/bilirubin (Yamashita
et al., 2004; Gozzelino et al., 2010). CO can exert cytoprotective
effects via the modulation of cellular signal pathways, including
the p38 mitogen activating protein kinase (Ndisang et al., 2003).
In addition, CO can bind Fe in the heme pockets of hemoproteins,
inhibiting heme release and preventing its cytotoxic effects (Seixas
et al., 2009; Ferreira et al., 2011). On the other hand, biliverdin
has been described to participate in an antioxidant redox cycle in
which, once produced by HO, biliverdin is reduced to bilirubin
by biliverdin reductase. This is followed by the subsequent oxi-
dation of bilirubin by ROS back to biliverdin, forming a catalytic
antioxidant cycle that is driven by NADPH, the reducing cofactor
of biliverdin reductase. This cycle has the ability to strongly sup-
press the oxidizing and toxic potential of hydrogen peroxide and
other ROS, thus acting as one of the most powerful anti-oxidant
physiological system.
Another detoxifying system is represented by ferritin, an evolu-
tionarily conserved Fe sequestering protein that acts as the major
intracellular depot of non-metabolic iron (Balla et al., 1992a,b;
Berberat et al., 2003; Cozzi et al., 2004; Pham et al., 2004). Ferritin
is a multimeric protein composed of 24 subunits of two types,
the heavy chain (H-Ft) and the light chain (L-Ft) and has a very
high capacity for storing iron (up to 4500mol of iron per mol
of ferritin). H-Ft manifests ferroxidase activity that catalyses the
oxidation of ferrous iron to ferric iron, thus favoring its storage in
L-Ft (Hentze et al., 2004) and limiting its participation in the pro-
duction of free radicals via Fenton reaction (Pham et al., 2004).
Together, HO and ferritin allow rapid shifting of iron from heme
into ferritin core where it is less available to catalyze deleterious
reactions. By increasing the expression of HO-1 and ferritin, cells
can survive to lethal heme-induced oxidative stress (Balla et al.,
2005; Gozzelino and Soares, 2013).
CONTROL OF HEME EXPORT
Recent evidence demonstrated that also heme export out of the
cell significantly contributes to the regulation of intracellular
heme levels. Two heme exporters located at the plasmamembrane
have been identified to date: FLVCR1a and ABCG2 (ATP-Binding
Cassette, subfamily G, member 2) (Figure 2).
The plasma heme exporter FLVCR1a
FLVCR1a was originally identified and cloned as a cell-surface
protein receptor for feline leukemia virus subgroup C, causing
pure red blood cell aplasia in cats (Tailor et al., 1999; Quigley et al.,
2000). The role of FLVCR1a as a plasmamembrane heme exporter
is suggested by several in vitro data. Indeed, the overexpression
of FLVCR1a in NRK or HeLa cells causes a slight but significant
decrease of heme content whereas its silencing in FEA or HeLa
cells enhances heme level (Quigley et al., 2004; Chiabrando et al.,
2012). In addition, the ability of FLVCR1a to export cytoplasmic
heme has been demonstrated using zinc mesoporphyrin (ZnMP),
a fluorescent heme analog, and 55Fe-heme (Quigley et al., 2004).
The heme export activity of FLVCR1a is regulated by the presence
of plasma proteins with high affinity for heme, like Hx (Yang et al.,
2010).
The analysis of the role of FLVCR1a in vivo is limited by the
complexity of the available mouse models of Flvcr1 deficiency
(Table 1). It was initially reported that FLVCR1a plays an essential
role during erythropoiesis, by preventing the toxic accumulation
of heme in erythroblasts (Keel et al., 2008). This hypothesis was
suggested by the observation that mice lacking Flvcr1 die in utero
due to an impairment of erythroid differentiation at the proery-
throblast stage. Similarly, post-natal mice lacking Flvcr1 show a
block of erythroid maturation leading to hyperchromic, macro-
cytic anemia and reticulocytopenia (Keel et al., 2008). Following
the identification of FLVCR1b, it was realized that these mouse
models were likely lacking both FLVCR1a and FLVCR1b, as they
were generated by the deletion of the third exon of the Flvcr1 gene,
which is common to both Flvcr1 isoforms. Thus, the described
phenotype was due to FLVCR1a and/or FLVCR1b deficiency. The
specific expression of the two FLVCR1 isoforms in these mouse
models still remain to be experimentally verified. Recently, the
generation and analysis of Flvcr1a−/− mice suggested that the
previously described phenotype was mainly due to the absence
of FLVCR1b, since mice lacking FLVCR1a but still expressing
FLVCR1b show normal erythroid differentiation and die in utero
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due to severe hemorrhages, edema and skeletal malformations
(Figure 3). Taken together, these data suggest that FLVCR1b, by
exporting heme from mitochondria, is essential for fetal ery-
throid differentiation (Chiabrando et al., 2012). These data do
not exclude a role for FLVCR1a during erythropoiesis; probably
the two FLVCR1 isoforms cooperate to determine the appropriate
heme level needed for erythroid differentiation (Figure 4A).
As FLVCR1a is ubiquitously expressed, it has been hypothe-
sized that its heme export activity could be relevant in different
tissues. Post-natal mice lacking Flvcr1 show iron overload in hep-
atocytes, duodenal enterocytes and splenic macrophages (Keel
et al., 2008). In this mouse model the observed phenotype could
not be easily attributed to one of the two isoforms since both
FLVCR1a and FLVCR1b were deleted. The specific contribution
of FLVCR1a isoform to heme export became evident in condi-
tional mice lacking FLVCR1a expression in hepatocytes. These
FIGURE 3 | The loss of the heme exporter FLVCR1a in mice causes
embryonic lethality, skeletal malformation and extended
hemorrhages. (A) Stereoscopic view of a wild-type (left) and a Flvcr1a−/−
(right) embryo at the embryonic stage of E14,5. At this stage, the wild-type
embryo shows normal skeletal structure, with fully formed limbs. The
Flvcr1a−/− embryo shows extended hemorrhages and edema through the
body, in particular in the limbs, back and head. Flvcr1a−/− embryos show
skeletal malformations, as suggested by the absence of the lower jaw and
properly formed digits. (B) An enlarged view of E15,5 wild-type and
Flvcr1a−/− anterior limbs (marked with a broken line). In the Flvcr1a−/−
embryo, the limbs show severe hemorrhage, leading to impairment in limb
and toe formation.
mice accumulate heme and iron in the liver as a consequence
of FLVCR1a suppression (Vinchi et al., 2014). Additionally, they
show HO and ferritin upregulation, together with alteration of
the hepatic oxidative status and induction of the antioxidant
genes. These data suggest that heme is normally exported intact
from these cells and that in the absence of FLVCR1a, the heme
degrading and iron storage systems are upregulated as an attempt
to compensate for the lack of heme export (Figure 4B).
The analysis of conditional Flvcr1a−/− mice in hepato-
cytes demonstrated a crucial role for FLVCR1a in the mainte-
nance of hepatic heme homeostasis and hemoprotein function.
Interestingly, FLVCR1a expression was found upregulated dur-
ing cytochrome induction, suggesting that hepatic heme export
activity of FLVCR1a was closely associated with heme biosynthe-
sis required to sustain new cytochrome synthesis. Indeed, the lack
of FLVCR1a in hepatocytes caused the expansion of the cytoso-
lic heme pool that was responsible for the early inhibition of
heme synthesis and increased degradation of heme. As a result,
the expression as well as the activity of cytochromes P450 was
reduced. These findings indicate that FLVCR1a-mediated heme
export is crucial to control intracellular heme levels that in turn
regulate heme synthesis, thus determining cytochrome function
in the liver (Vinchi et al., 2014).
Additionally, the analysis of Flvcr1a−/− embryos highlighted
a previously unrecognized role for FLVCR1a in the maintenance
of endothelial integrity. Flvcr1a−/− embryos are characterized by
reduced vasculature development and complexity. This is partic-
ularly evident in the limbs and tail, where vessels do not form
properly and branching is severely compromised (Chiabrando
et al., 2012) (Figure 3). The molecular mechanism leading to
the observed phenotype is still unknown. Interestingly, FLVCR1a
is regulated at the transcriptional level by hypoxia, which has a
well-established role in angiogenesis and vasculogenesis (Fiorito
et al., 2014). We hypothesize a role for FLVCR1a in preventing
heme-induced oxidative stress in endothelial cells (Figure 4C).
FLVCR1a mediated heme export could work in strong associa-
tion with HO-1 to determine the appropriate amount of heme
in endothelial cells. It is well established that HO-1 plays a piv-
otal role in the regulation of vascular biology (Belcher et al.,
2006, 2010; Stocker and Perrella, 2006; Kim et al., 2011). For this
reason, it will be interesting to investigate the role of FLVCR1a
in hemolytic disorders characterized by enhanced heme-induced
oxidative stress in endothelial cells.
The understanding of FLVCR1a subcellular localization, par-
ticularly in polarized cell types, will help to gain new insight in
FLVCR1a role and function. To date, it has been reported that
FLVCR1a localizes on the sinusoidal membrane of hepatocytes,
likely exporting heme in the bloodstream (Vinchi et al., 2014).
These results have been obtained by studies on the overexpressed
protein and are limited by the lack of specific antibodies for this
exporter that prevents any analysis of the localization of endoge-
nous FLVCR1a. Future work is required to specifically address
FLVCR1a localization in different cell types in vivo.
The plasma heme exporter ABCG2
ABCG2 (ATP-binding cassette, sub-family G, member 2; also
known as BRCP, breast cancer resistance protein) is a member
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FIGURE 4 | The heme exporter FLVCR1a acts as a new heme
detoxifying system. (A) Erythroid progenitors are able to synthesize and
handle high amount of heme, in view of their hemoglobin (Hb)-mediated
oxygen transport activity. FLVCR1b acts as a mitochondrial heme exporter
to allow newly formed heme release from the mitochondrion to the
cytosol, where it is incorporated into hemoproteins. FLVCR1a has been
described as a system involved in the control of heme levels inside
erythroid progenitors. By mediating heme export out of these cells,
FLVCR1a regulates intracellular heme amount, thus limiting free heme
toxicity and oxidative damage. (B) Hepatocytes have the highest rate of
heme synthesis after the erythroid progenitors. Hepatic heme is mostly
used for synthesis of P450 enzymes, which metabolize endogenous
compounds and xenobiotics. FLVCR1a mediates heme export out of
hepatocytes, thus maintaining hepatic heme homeostasis and controlling
cell oxidative status. FLVCR1a export function allows the maintenance of
a proper cytosolic heme pool that matches cell need for new
hemoprotein generation (e.g., cytochrome P450). Block of heme export
causes heme pool expansion leading to the inhibition of heme synthesis
and the reduction of cytochrome activity. (C) A similar role for FLVCR1a
was proposed to occur in endothelial cells. Flvcr1a−/− embryos show
reduced vascular arborization, potentially due to altered endothelial
integrity, suggesting that the lack of FLVCR1a leads to intracellular heme
overload and oxidative stress. Endothelial cells are highly sensitive to
heme overload and, in this context, FLVCR1a function could be of crucial
importance to export heme excess, thus maintaining heme homeostasis
and controlling heme-induced oxidative stress.
of the ABC transporter family that was originally found to con-
fer drug resistance in breast cancer cells (Doyle et al., 1998).
The Abcg2 gene is located on human chromosome 4q22 and it
consists of 16 exons and 15 introns (Bailey-Dell et al., 2001).
ABCG2 is a “half transporter” as it has only one ABC cassette in
a single polypeptide chain of 70 kDa that consists of six trans-
membrane domains. Only the homodimer is functional (Kage
et al., 2002). Abcg2 expression is regulated by hypoxia through
Hypoxia Inducible Factor (HIF) 1 (Krishnamurthy et al., 2004).
ABCG2 is localized at the plasma membrane and it is expressed
in several tissues including hepatic canalicular membranes, renal
proximal tubules, intestinal epithelium and placenta (Doyle and
Ross, 2003). In all these tissues, ABCG2 detoxifies drugs, tox-
ins and metabolites (Bailey-Dell et al., 2001). Moreover, ABCG2
is expressed in a sub-population of hematopoietic stem cells. It
prevents cytotoxicity of chemotherapics and confers resistance to
hypoxic conditions (Krishnamurthy et al., 2004).
ABCG2 has a wide substrate specificity (Keppler and Konig,
2000). Recently, genetic studies in human disease established that
ABCG2 functions as a urate transporter that promotes urate
excretion in the kidney as discussed in section Hyperuricaemia
and Gout (Qiu et al., 2006). The role of ABCG2 as a heme
transporter was serendipitously discovered when Abcg2−/− mice
fed a modified diet developed skin photosensitivity (Jonker
et al., 2002). This was caused by the accumulation of pheophor-
bide, a degradation product of chlorophyll present in the diet,
structurally similar to PPIX. Abcg2−/− mice were found to
accumulate PPIX and other porphyrin-like compounds in ery-
throcytes and other cells implying that ABCG2 has a role in
cellular efflux of these compounds (Jonker et al., 2002). In addi-
tion, it has been demonstrated that ABCG2 is precipitated by
hemin-agarose and it exports the heme analog ZnMP in K562
cells transfected with the human Abcg2 cDNA (Krishnamurthy
et al., 2004; Desuzinges-Mandon et al., 2010). Nevertheless,
the physiologic porphyrin substrate of ABCG2 seems to be
PPIX as erythroid progenitors of Abcg2−/− mice accumulate
this compound and erythroid cells overexpressing ABCG2 have
reduced levels of PPIX (Krishnamurthy and Schuetz, 2005; Zhou
et al., 2005). Interestingly, erythroid progenitors of Abcg2−/−
mice are more sensitive to hypoxic conditions. Since Abcg2
expression is induced by HIF1, ABCG2 is thought to confer a
strong survival advantage to stem cells under hypoxic stress by
reducing intracellular porphyrin content (Krishnamurthy et al.,
2004).
Despite of porphyrin accumulation in erythroid progenitors,
Abcg2−/− mice do not show porphyria or an overt anemic phe-
notype. This might indicate that pophyrin export does not signif-
icantly contribute to intracelluar porphyrin homeostasis and/or
that compensatory mechanisms are activated when Abcg2 is lack-
ing. Alternatively, this could also indicate that ABCG2 is not a
physiologic porphyrin exporter. Nevertheless, ABCG2 expression
is induced in HeLa cells after the stimulation of heme synthesis
(Chiabrando et al., 2012), supporting the conclusion that, in some
way, it is involved in this process.
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Based on its localization at the apical membrane of duodenal
enterocytes, it has been hypothesized that ABCG2 could trans-
port excess heme or porphyrin from the enterocyte to the lumen.
Similarly, it could be involved in porphyrin/heme detoxification
through the biliary system and/or the kidney (Latunde-Dada
et al., 2006; Krishnamurthy et al., 2007). Consistently, ABCG2
was found to cooperate with HO-1 to protect kidney cells against
heme-induced cytotoxicity (Wagener et al., 2013). Finally, Abcg2
deficiency was found to increase oxidative stress and to exacer-
bate cognitive/memory deficit in a mouse model of Alzheimer’s
disease (Zeng et al., 2012).
Thus, ABCG2 is a plasma membrane transporter for a wide
variety of substrates including urate porphyrin/heme, chemio-
therapeutics, antibiotics, xenobiotics, and food metabolites. If,
other than in urate transport and in drug metabolism, ABCG2
plays a role in heme export under physiologic or pathologic
conditions remains to be elucidated.
CONTROL OF HEME IMPORT
A further level of control of intracellular heme content is rep-
resented by the modulation of heme import inside the cells
(Figure 2). To date the only known proteins with a well-
established function as heme importers are HRGs (Rajagopal
et al., 2008; White et al., 2013), reviewed by Hamza et al. in the
present Research Topic. Two other putative heme importers have
been described, the Feline leukemia virus subgroup C receptor 2
(FLVCR2) and the Heme carrier protein 1/Proton-coupled folate
transporter (HCP1/PCFT).
The heme importer FLVCR2
FLVCR2 is the secondmember of the SLC49 family of heme trans-
porters, a family also including the founding member FLVCR1
(SLC49A1), and other two proteins, MFSD7 (SLC49A3) and
DIRC2 (SLC49A4) (Khan and Quigley, 2013). The SLC49 family
belongs to the Major Falicitator Superfamily (MFS) of secondary
active permeases that transports small solutes across membranes
in response to chemico-osmotic gradients, contributing to the
maintenance of normal cell homeostasis (Pao et al., 1998).
The gene encoding FLVCR2 contains 10 exons, is located on
chromosome 12D2 in mouse and 14q24 in human (Quigley et al.,
2000) and is highly homologous to the Flvcr1 gene. FLVCR2
protein shares about 60% amino acid sequence identity with
FLVCR1. A variant transcript exists, encoding a shorter hypothet-
ical protein that differs in the N-terminal and whose significance
is unknown (Brown et al., 2006).
Flvcr2mRNA is found ubiquitously, with the highest transcript
levels observed in human brain, placenta, lung, liver, kidney and
hematopoietic tissues (Duffy et al., 2010). Inmouse, its expression
has been reported in brain, spinal cord (Lein et al., 2007) and in
the columnar cells overlying the fetal blood vessels in the placental
yolk sac at day E20 (Brasier et al., 2004).
The FLVCR2 protein is composed by 12 predicted transmem-
brane domains and six presumptive extracellular loops, it is not
N-linked glycosylated and shows a molecular mass of about 55-
kDa, while its truncated variant weights about 40 kDa (Brown
et al., 2006). Unfortunately, to date a FLVCR2-specific antibody
is not available, so protein expression in the different tissues
and cell compartments has not been determined. Nevertheless,
the FLVCR2 functions, described below, strongly indicate its
localization on the cell plasma membrane.
Brasier et al. (2004) proposed a putative role for FLVCR2 as
a calcium transporter, based on its expression in murine and
human tissues characterized by rapid calcium exchange. Although
this function has not been formally excluded by subsequent stud-
ies, alternative roles for FLVCR2 have emerged. FLVCR2 has been
identified as the receptor for the FY981 variant of FeLV-C retro-
virus, a variant that can also use FLVCR1 and the thiamine
transporter 1 to infect cells (Shalev et al., 2009). Unlike FLVCR1,
FLVCR2 was unable to export heme (Quigley et al., 2004).
Conversely, FLVCR2 was postulated to be a heme importer since
(i) the overexpressed protein coprecipitated with hemin-agarose,
(ii) human cells overexpressing FLVCR2 showed an enhanced
uptake of ZnMP, and (iii) Xenopus oocytes expressing human
FLVCR2 showed increased uptake of [55Fe]hemin (Duffy et al.,
2010). Nevertheless, it has to be noted that the binding of FLVCR2
to hemin-agarose was not very efficiently competed by free hemin
and the transport assays showed only a two-fold increase of
ZnMP or 55Fe-heme uptake when FLVCR2 was overexpressed.
Furthermore, studies in yeast failed to demonstrate a heme trans-
port function for FLVCR2 (Yuan et al., 2012). Finally, genetic
studies in humans associated Flvcr2 mutation to the Fowler syn-
drome, a disorder with no obvious link to heme metabolism (see
section Fowler Syndrome). Thus, the assumption that FLVCR2 is
a heme importer is not definitive and further studies are needed
to fully address the substrate specificity of this transporter.
The heme importer HCP1/PCFT
HCP1/PCFT belongs to the SLC46 family of the MFS. The gene
encoding HCP1/PCFT spans five exons and four introns and is
located on chromosome 11B5 inmouse and 17q11 in human. The
HCP1/PCFT protein is highly conserved among different species,
sharing about 90% similarity between human and mouse or rat
(Qiu et al., 2006). Furthermore, it shows a significant homology
to bacterial metal tetracycline transporters, likely due to similar-
ities in the structures of the substrates specific for HCP1/PCFT
and this kind of transporters (Shayeghi et al., 2005).
Hcp1/Pcft transcript is abundant in themouse duodenum after
weaning and in the adult rat liver (Shayeghi et al., 2005), but
a weak expression can also be detected in the mouse kidney
(Shayeghi et al., 2005) and in many other mouse tissues (Salojin
et al., 2011). No expression was observed in mouse placenta and
ileum (Shayeghi et al., 2005) and in mouse adipose tissue or
total bone tissue including bone marrow (Salojin et al., 2011). In
human tissues, two differentHcp1/Pcft transcripts were observed,
the shorter one being dominant. Both transcripts were detected
in kidney, liver, placenta, duodenum and spleen, and to a lesser
extent in jejunum, ileum, cecum, colon, rectum, and testis. Very
low Hcp1/Pcft mRNA levels were observed in human brain, lung,
stomach, heart and muscle (Qiu et al., 2006). Furthermore, the
Hcp1/Pcft transcript was found in human macrophages (Schaer
et al., 2008), in retina and in retinal pigment epithelium (Sharma
et al., 2007). Finally, Hcp1/Pcft mRNA was also observed in sev-
eral cell lines, like hepatoma, neuroblastoma and macrophage cell
line (Shayeghi et al., 2005), in primary rat astrocytes (Dang et al.,
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2010) and in the Caco2 human adenocarcinoma cell line (Qiu
et al., 2006).
Duodenal Hcp1/Pcft mRNA levels are not influenced by sys-
temic iron amount or by increased ineffective erythropoiesis and
IREs were not observed in the 5′ and 3′ untranslated regions of
Hcp1/Pcft transcript (Shayeghi et al., 2005). Conversely,Hcp1/Pcft
mRNA levels strongly increase upon hypoxia, despite the absence
of hypoxia responsive elements in the promoter sequence of
the Hcp1/Pcft gene. Moreover, the anti-inflammatory agents glu-
cocorticoids increase Hcp1/Pcft mRNA in macrophages (Schaer
et al., 2008), while the lipopolysaccharide and Toll-like receptors
agonists lead to suppression of Hcp1/Pcft transcript in these cells.
The HCP1/PCFT protein contains 459 amino acids, shows a
molecular mass of about 50 kDa, is composed of 9 (Shayeghi
et al., 2005) or 12 (Sharma et al., 2007) predicted transmem-
brane domains and is localized both in the plasma membrane
(particularly the apical membrane of polarized cells like entero-
cytes) and in subcellular vesicles (Shayeghi et al., 2005; Yanatori
et al., 2010). In non-polarized cells, it could also localize in the
lysosome (Yanatori et al., 2010), and in human macrophages it
has been detected in the endosome (Schaer et al., 2008). The
localization of HCP1/PCFT is highly influenced by changes in cel-
lular iron stores, accumulating at the brush border membrane in
iron-deficiency, and in the cytoplasm in iron-loaded conditions
(Shayeghi et al., 2005).
HCP1/PCFT was initially identified as a heme importer
(Shayeghi et al., 2005). Nevertheless, Qiu et al. (2006) reported
that HCP1/PCFT is a folate transporter (Qiu et al., 2006).
Considering that the Km at pH 6.5 for 5-methyltetrahydrofolate
was measured at 0.8μMwhereas the Km at neutral pH for hemin
was 125◦μM, it appears that HCP1/PCFT is a poor heme trans-
porter. This conclusion is strengthened by the finding that the
gene coding for HCP1/PCFT was found mutated in patients with
hereditary folate malabsorption (Qiu et al., 2006) (see section
Hereditary Folate Malabsorption Syndrome).
Here, we report some other considerations on the putative
role of HCP1/PCFT as a heme importer that could be relevant
only in some cell types or in particular physiologic or patho-
logic situations. The expression of HCP1/PCFT in the duodenum
and liver indicate that this protein might be important both for
the import of dietary heme from the gut lumen to the entero-
cytes and for the uptake of plasma heme by non-intestinal tissues
(Shayeghi et al., 2005). Moreover, it has been proposed that it
could be involved in the export of hemoglobin-derived heme
from the endosome to the cytoplasm of macrophages (Schaer
et al., 2008). In addition to free heme import, both heme-arginine
and heme-bovine serum albumin are able to donate heme for
uptake via HCP1/PCFT. Nevertheless, in primary rat astrocyte
cultures the greatest amount of heme accumulation wasmeasured
in the absence of Hx/albumin-containing fetal calf serum (Dang
et al., 2010). The transport of heme by HCP1/PCFT is a saturable
and energy/temperature-dependent process. HCP1/PCFT is able
to import other substrates containing a porphyrin ring, as ZnMP
and protoporphyrin (Shayeghi et al., 2005; Qiu et al., 2006).
The energy source for HCP1/PCFT-mediated heme transport
is unknown, as no adenosine triphosphate binding motifs were
observed in its sequence. Nevertheless, the prevalent hypothesis
is that, as for folates uptake, it could utilize the co-transport of
protons along a favorable concentration gradient to drive the
transport of heme (Shayeghi et al., 2005).
PATHOLOGICAL CONDITIONS ASSOCIATED WITH
ALTERATIONS OF HEME METABOLISM
PATHOLOGICAL CONDITIONS ASSOCIATED WITH ALTERATIONS OF
EXTRACELLULAR HEME SCAVENGING
Many pathological conditions are associated with hemolysis and
extracellular heme release. Among them, sickle cell anemia,
β-thalassemia, malaria, paroxysomal nocturnal hemoglobinuria
are the most paradigmatic (Gozzelino et al., 2010). In all these
conditions, the pool of circulating Hx is diminished and, conse-
quently, the plasma heme scavenging capacity is strongly reduced.
In the last decade, the use of a knockout mouse model for Hx
was valuable to elucidate its function as well as its potential use as
a therapeutic molecule in the prevention of heme adverse effects
(Table 1). Additionally, other functions of Hx not clearly related
to its role as an heme scavenger, have also been described thanks
to the use of knock-out mice (Fagoonee et al., 2008; Spiller et al.,
2011; Rolla et al., 2013).
Works on Hx−/− mice have demonstrated that these ani-
mals have alterations in heme/iron homeostasis in the duodenum
(Fiorito et al., 2013) and brain (Morello et al., 2009, 2011),
are highly sensitive to acute hemolysis (Vinchi et al., 2008) and
show a defective recovery after intravascular hemolysis, suffer-
ing from severe renal damage associated with iron loading and
lipid peroxidation (Tolosano et al., 1999, 2002). After acute heme
overload, Hx−/− mice develop severe hepatic red blood cell con-
gestion associated to cell iron redistribution, lipid peroxidation
and inflammation. This is likely due to the increased endothe-
lial activation and vascular permeability occurring in Hx−/− mice
compared to wild-type controls (Vinchi et al., 2008). Endothelial
activation is a proinflammatory and procoagulant state of the
endothelial cells lining the lumen of blood vessels. This state
is mainly characterized by an increased expression of adhesion
molecules on endothelial cell surface, which promotes the adher-
ence of leukocytes as well as platelets and red blood cells, thus
favoring inflammation, clot and eventually thrombus formation.
According to its function as a free heme scavenger, Hx is expected
to counteract heme toxicity on the vascular endothelium and
increasing experimental evidence is supporting this concept.
Similarly, sickle cell disease and β-thalassemia mice show
heme-driven endothelial activation, vaso-occlusion and cardio-
vascular dysfunction that could be efficiently recovered through
the administration of an Hx-based therapy (Vinchi et al., 2013).
This recent observation further strengthens the concept that
heme triggers vascular inflammation and damage, and empha-
sizes the importance of Hx in counteracting heme-driven cardio-
vascular dysfunction associated with hemolytic conditions. This
could have relevance, in the future, for therapeutic interventions
against cardiovascular and endothelial dysfunctions in hemolytic
patients (Vinchi and Tolosano, 2013).
Malaria is another well-known hemolytic condition, associ-
ated with the accumulation of high concentrations of free heme
in plasma. The appearance of hemoglobin and heme in plasma
has been linked to the development of cerebral malaria, which
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remains the most severe and difficult to treat complication of the
infection (Ferreira et al., 2008; Seixas et al., 2009). The potential
protective effect of both Hp and Hx in this pathology still needs
to be elucidated.
Recently, hemolysis has been observed to occur after red
blood cell transfusion, one of the most common therapeutic
interventions in medicine. Over the last two decades, however,
transfusion practices have been restricted, limiting unnecessary
transfusions (Barr and Bailie, 2011). The adverse effects of trans-
fusions seem to be mainly related to the storage period between
blood donation and transfusion (Wang et al., 2012). Transfusions
of old blood in animal models result in both intravascular and
extravascular hemolysis and cause hypertension, acute renal fail-
ure, hemoglobinuria, and vascular injury. Conversely, old blood
transfusion together with the hemoglobin scavenger Hp attenu-
ated most of the transfusion-related adverse effects (Baek et al.,
2012; Schaer et al., 2013b). Whether a similar protection, alone or
in association with Hp, could be afforded by Hx still needs to be
explored.
Not long ago, severe sepsis was found accompanied by hemol-
ysis and Hx exhaustion in mice (Larsen et al., 2012). Larsen and
coworkers showed that the administration of exogenous Hx was
protective against organ injury and prevents the lethal outcome
of severe sepsis in mice (Larsen et al., 2010). The protective effect
in this model is related to the ability of Hx to counteract heme
proinflammatory effects upon pathogen infection.
Furthermore, a neuroprotective effect for Hx was also
described. Hx was found expressed by cortical neurons and
present in mouse cerebellum, cortex, hippocampus, and stria-
tum. Upon experimental ischemia, neurologic deficits as well
as infarct volumes in the brain were increased in Hx deficient
mice, indicating that Hx regulates extracellular free heme levels
and the heme-Hx complexes protect primary neurons against the
heme-induced toxicity (Li et al., 2009).
The rationale for the use of Hx as a therapeutic is based
on the idea that it acts by scavenging circulating free heme,
the ultimate mediator of hemoglobin toxicity. In particular, the
crucial role of Hx in the protection from heme toxicity has
relevance to pathological conditions associated with hemoly-
sis that are often characterized by partial/total exhaustion of
hemoglobin/heme scavengers. Therefore, replenishing the circu-
lating stores of heme scavengers, thereby compensating for the
loss of heme scavenging capacity in plasma, may be used as a ther-
apeutic approach to target circulating free heme and prevent its
deleterious effects (Schaer and Buehler, 2013; Schaer et al., 2013b;
Vinchi and Tolosano, 2013). The recent demonstration of the
effectiveness of an Hx therapy in mouse models of sickle cell ane-
mia, β-thalassemia and sepsis opens new perspectives concerning
the use of this molecule as a new therapeutic drug in hemolytic
diseases.
To date, we are still far from the use of heme scavengers as ther-
apeutics and no clinical trials are ongoing. Anyway, the possible
use of these molecules for therapeutic purposes has elicited the
interest of the research community in the field as well as of several
pharmaceutical companies. Pre-clinical studies are ongoing with
the aim of translating the protective effects of heme scavengers
into clinical practice in the near future.
PATHOLOGICAL CONDITIONS ASSOCIATED WITH ALTERATIONS OF
HEME SYNTHESIS
Porphyrias
Eight distinct types of inherited porphyrias have been described,
each resulting from a partial deficiency of a specific enzyme
of the heme biosynthetic pathway (Figure 2 and Table 2). The
porphyrias are characterized by an impairment of heme syn-
thesis, leading to the accumulation of specific intermediates of
the heme biosynthetic pathway in various tissues. Depending on
the primary site of overproduction and accumulation of heme
precursors, the porphyrias have been traditionally classified as
“hepatic” or “erythropoietic.” However, many types of porphyr-
ias have overlapping features. The accumulation of porphyrins in
different tissues leads to hepatic and hematopoietic alterations,
neurological and/or cutaneous symptoms.
Three different types of “erythropoietic protoporphyria” have
been described. The initial accumulation of the porphyrin precur-
sors occurs primarily in bone marrow erythroid cells. Mutations
in the FECH gene cause erythropoietic protoporphyria (EPP;
OMIM: #177000) (Gouya et al., 2002); the partial deficiency of
FECH leads to the accumulation of free-PPIX in bone marrow,
erythrocytes, plasma and finally in the liver (Murphy, 2003; Lecha
et al., 2009). A clinically indistinguishable form of erythropoietic
protoporphyria, named X-linked erythropoietic protoporphyria
(XLEPP; OMIM: #300752), is due to gain of function mutations
in the ALAS2 gene (Whatley et al., 2008). The overexpression
of ALAS2 causes an increased PPIX production in spite of nor-
mal FECH activity; as iron became limiting, FECH uses its
alternative metal substrate leading to the accumulation of Zn-
protoporphyrin in erythrocytes. The major phenotype of EPP
and XLEPP is porphyrin-induced photosensitivity. Hypochromic,
microcytic anemia is also common and the disorders may evolve
to severe hepatobiliary disease and hepatic failure (Anstey and
Hift, 2007; Whatley et al., 2008; Lecha et al., 2009). Mutations
in the UROS gene cause the third form of erythropoietic proto-
porphyria, called congenital erythropoietic protoporphyria (CEP;
OMIM: #263700); the partial loss of UROS activity leads to the
incomplete metabolism of hydroxymethylbilane and the accumu-
lation of non-physiologic porphyrin isomers in the bone marrow,
erythrocytes, urine and other organs. CEP is mainly character-
ized by cutaneous photosensitivity and hemolytic anemia (Sassa
and Kappas, 2000; Murphy, 2003; Bishop et al., 2006).
The “hepatic porphyrias” are characterized by the overpro-
duction and initial accumulation of porphyrin precursors in
the liver. Five different types of hepatic protoporphyria have
been described. Mutations in the ALAD, HMBS, CPOX, PPOX
genes cause different forms of acute hepatic porphyrias: Alad-
deficiency porphyria (ADP; OMIM: #612740), acute intermittent
porphyria (AIP; OMIM: #176000), hereditary coproporphyria
(HCP; OMIM: #121300) and porphyria variegate (VP; OMIM:
#176200), respectively. These disorders are characterized by the
accumulation of ALA, porphobilinogen and/or porphyrins pri-
marily in the liver. Themajormanifestations of these disorders are
the life-threatening acute neurologic attacks and abdominal pain
(Balwani and Desnick, 2012). Mutations in the Urod gene cause a
cutaneous form of hepatic porphyria, called porphyria cutaneous
tarda (PCT; OMIM: #176100); impaired UROD activity leads to
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Table 2 | Disorders associated to mutations in genes involved in heme metabolism.
Disease name Omim Genetic defect Disease features
X-linked erythropoietic protoporphyria (XLEPP) 300752 ALAS2 Erythropoietic Porphyria: immediate photosensitivity;
secondary liver disease; microcytic anemia
Alad-deficiency porphyria (ADP) 612740 ALAD Hepatic Porphyria: acute neurological attacks; abdominal
pain
Acute intermittent porphyria (AIP) 176000 HMBS Hepatic Porphyria: acute neurological attacks
Congenital erythropoietic protoporphyria (CEP) 263700 UROS Erythropoietic Porphyria: photosensitivity; hemolytic
anemia
Porphyria cutaneous tarda (PCT) 176100 UROD Hepatic Porphyria: photosensitivity; blisterin skin lesions;
liver disease
Hereditary coproporphyria (HCP) 121300 CPOX Hepatic Porphyria: acute neurological attacks; abdominal
pain; vesiculoerosive skin disease photosensitivity
Porphyria variegate (VP) 176200 PPOX Hepatic Porphyria: acute neurological attacks; abdominal
pain; vesiculoerosive skin disease; neurovisceral symptoms
photosensitivity
Erythropoietic protoporphyria (EPP) 177000 FECH Erythropoietic Porphyria: photosensitivity; secondary liver
disease; microcytic anemia
X-linked sideroblastic anemia (XLSA) 300751 ALAS2 Microcytic anemia with ringed sideroblasts
Human HO-1 Deficiency 614034 HO1 Hemolytic anemia, asplenia, renal and hepatic iron
deposition, endothelial dysfunction/vasculitis
Posterior column ataxia and retinitis pigmentosa (PCARP) 609033 FLVCR1 Sensory ataxia; Retinitis Pigmentosa
Hyperuricaemia and Gout 138900 ABCG2 Metabolism disorder, local immune-mediated inflammatory
reaction
Fowler syndrome (FS) 225790 FLVCR2 Cerebral glomeruloid vasculopathy; limb deformities
Hereditary Folate Malabsorption syndrome (HFM) 229050 HCP1/PCFT Systemic and cerebrospinal folate deficiency; anemia;
pancytopenia; hypoimmunoglobulinemia; developmental
delay; cognitive impairment; epilepsy
the accumulation of uroporphyrin and other highly carboxylated
porphyrins in the skin, liver and erythrocytes. PCT is character-
ized by blistering skin lesions that appear most commonly on
the backs of the hands (increased cutaneous photosensitivity) and
liver disease whereas neurologic features are usually absent (Frank
and Poblete-Gutierrez, 2010; Balwani and Desnick, 2012).
The generation of animal models of porphyrias allowed a bet-
ter understanding of the pathophysiological mechanisms involved
in the distinct types of porphyria as well as the development of
novel therapeutic strategies (Richard et al., 2008).
Sideroblastic anemias
Mutations in the ALAS2 gene are responsible for the most
common form of inherited sideroblastic anemia, named X-linked
sideroblastic anemia (XLSA; OMIM: #300751) (Table 2).
Sideroblastic anemias are genetically and clinically heteroge-
neous disorders characterized by the pathological accumulation
of iron in the mitochondria of erythroid precursors. XLSA
is due to loss of function mutations in the ALAS2 gene
(Bergmann et al., 2010; Ducamp et al., 2011) or mutations
in an enhancer of ALAS2 gene that cause the disruption of a
GATA binding site important for its transcriptional regulation
(Kaneko et al., 2013). The reduced activity of ALAS2 causes
an impairment of heme biosynthesis; as PPIX production is
decreased, excess iron accumulates in perinuclear mitochon-
dria of erythroblasts creating a ring-like appearance and thus
the characteristic “ringed sideroblasts.” XLSA patients are
characterized by hypochromic, microcytic anemia of variable
severity.
The role of ALAS2 in XLSA has been confirmed in several ani-
mal models of the disease. Sauternes (sau) is a zebrafish mutant
characterized by a delay in erythroid differentiation, abnormal
globin gene expression and heme deficiency. Using positional
cloning strategies, it has been reported that the sau gene encodes
for ALAS2, thus confirming that loss of ALAS2 leads to a micro-
cytic, hypochromic anemia similar to XLSA (Brownlie et al.,
1998). The absence of Alas2 in mice causes embryonic lethality
due to a severe block of erythroid differentiation. In contrast to
human patients, ring sideroblasts are not present and iron depo-
sition occurs in the cytoplasm instead of mitochondria (Nakajima
et al., 1999; Harigae et al., 2003).
Interestingly, other forms of inherited sideroblastic ane-
mias are due to mutations in genes indirectly involved in the
heme biosynthetic pathway. Mutations in the gene coding for
SLC25A38, the putative mitochondrial exporter of ALA, have
been identified in patients with an autosomal recessive form of
sideroblastic anemia (Guernsey et al., 2009). In other patients,
mutations in the ATP-binding cassette transporter ABCB7 gene
or in GLUTAREDOXIN5 (GLRX5) gene have been identified
(Allikmets et al., 1999; Camaschella et al., 2007). Both ABCB7 and
GLRX5 are involved in the assembly of iron-sulfur clusters (Lill
and Muhlenhoff, 2006). Iron-sulfur clusters deficiency causes the
activation of IRP1,mitochondria iron accumulation and cytosolic
iron depletion that in turn activates IRP2. The activation of IRPs
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determines the translational repression of ALAS2 resulting in
sideroblastic anemia (Allikmets et al., 1999; Wingert et al., 2005;
Camaschella et al., 2007; Sheftel et al., 2009; Ye et al., 2010). Thus,
a primary defect in iron-sulfur clusters biogenesis secondarily
affects heme synthesis in erythroblasts, resulting inmitochondrial
iron loading and the same pathophysiology of ALAS2 deficiency.
PATHOLOGICAL CONDITIONS ASSOCIATED WITH ALTERATIONS OF
HEME DEGRADATION
Disorders associated with mutations in HO-1 gene
Mice lacking functional HO-1 were generated by Poss and
Tonegawa (1997) (Table 1). These mice were characterized by
serum iron deficiency and pathologic tissue iron-loading, indi-
cating that HO-1 is crucial for the expulsion of iron from tissue
stores and for its reutilization. HO-1−/− mice were shown to
accumulate, with age, hepatic and renal iron that contributed
to oxidative damage, tissue injury and chronic inflammation
(Yachie et al., 1999; Koizumi, 2007). These data demonstrated
that, although HO-1 is a stress-induced protein, it is impor-
tant under basal conditions to protect liver and kidney from
oxidative damage and that it is an essential regulator of iron
metabolism and homeostasis. Additionally, these mice suffered
from delayed growth and progressive chronic inflammatory dis-
eases as suggested by an enlarged spleen and lymph nodes, hepatic
inflammatory cell infiltrates, vasculitis, and glomerulonephri-
tis. Furthermore, they were found to be extremely sensitive to
oxidative injury and prone to hepatic necrosis and death upon
lipopolysaccharide administration.
Recent studies on HO-1−/− mice revealed that HO-1 defi-
ciency causes the depletion of resident splenic and liver
macrophages, due to their inability to catabolize hemoglobin-
derived heme during erythrophagocytosis (Kovtunovych et al.,
2010). In the spleen, initial splenic enlargement was observed
to progress to red pulp fibrosis, atrophy, and functional hypos-
plenism in older mice. Finally, the failure of tissue macrophages
to remove senescent red blood cells led to intravascular hemol-
ysis, circulating hemoglobin release, and iron redistribution to
hepatocytes and kidney proximal tubules. Indeed, the lack of
HO-1 strongly impairs macrophage function, thus causing iron
redistribution and severe oxidative tissue injury.
HO-1 deficiency in humans was described for the first time
in 1999 (OMIM: #614034) (Yachie et al., 1999; Kawashima
et al., 2002) (Table 2). The sequence analysis of the HO-1 gene
revealed the complete loss of exon 2 on the maternal allele and a
2-nucleotide deletion in exon 3 on the paternal allele. The disease
was reported in a 6-year-old boy, who suffered from severe growth
retardation, asplenia, marked hepatomegaly, renal injury, tissue
iron deposition and paradoxically elevated Hp levels. Moreover,
he showed increased red blood cells fragility, chronic hemoly-
sis, anemia, leukocytosis, thrombocytosis, disseminated intravas-
cular coagulation, hyperlipidemia and mesangio-proliferative
glomerular changes, likely resulting from endothelial injury and
reticulo-endothelial dysfunction.
The serum level of Hp is usually reduced in hemolytic states;
in this patient suffering from hemolytic anemia, however, the Hp
level was rather increased. In the HO-1 deficient case, Hp pro-
duction rather than its consumption could be increased due to a
dominant effect of inflammation. In addition, reticuloendothe-
lial dysfunction could delay the clearance of the Hp-hemoglobin
complex. Contrarily to the HO-1−/− mouse, in human HO-
1 deficiency fatty streaks and fibrous plaques were observed.
Histologically, the fibrous plaques were characterized by the pro-
liferation of smooth muscle cells and few foam macrophages.
The enhanced proliferation of smooth muscle cells could be a
consequence of HO-1 loss.
Recently, another case of HO-1 deficiency was described in a
15-year-old girl who presented massive hemolysis, inflammation,
nephritis and congenital asplenia (Radhakrishnan et al., 2011).
The key features that suggested HO-1 deficiency were marked
hemolysis, generalized inflammation with evidence of endothe-
lial injury and nephropathy with underlying asplenia. Mutation
analysis showed the presence of homozygous missense mutations
in exon 2 (R44X) on chromosome 22q12, which resulted in the
absence of the functional HO-1.
HO-1 deficiency in humans is characterized by total asplenia
and this is fully recapitulated by the mouse model of HO-1 defi-
ciency suggesting that this enzyme has a key role in macrophage
heme metabolism and heme-iron reutilization. On the other
hand, compared with the knockout mouse model, the human
cases of HO-1 deficiency were observed to involve more severely
the endothelial cells. Both the reported cases of HO-1 deficiency
presented endothelial dysfunction, systemic inflammation and
hemolysis. In particular, in the last reported case of HO-1 defi-
ciency, the initial trigger of cold antibody-mediated hemolytic
anemia, with intravascular hemolysis, would have resulted in
heme-induced endothelial damage. In both cases, signs of severe
endothelial damage in the form of raised inflammatory markers,
von Willebrand factor, and coagulopathy were found and these
children died of intracranial hemorrhage. It was proposed that
HO-1 deficiency results in a novel form of vasculitis or endothelial
injury syndrome. How asplenia modulated the disease is unex-
plained. In view of the absence of spleen in both cases, it is
possible that HO-1 gene expression may have a role in splenic
arteriogenesis, other than in angiogenesis, as already proposed.
This very rare condition provided important insight into the
functional role and importance of this enzyme. In both mice
and human cases, a severe proinflammatory and pro-oxidant
phenotype was noted, further highlighting the anti-oxidant,
anti-inflammatory and cytoprotective function of this enzyme.
Although it appears evident that HO-1 is essential to keep intra-
cellular heme levels within a physiologic non-toxic range, it is not
clear whether the protection against heme toxicity by this enzyme
mainly relies on its primary heme degrading activity, on the bio-
logic activities of its metabolic end products, namely CO and
bilirubin, or both.
DISORDERS INFLUENCED BY HO-1 POLYMORPHISMS
Humans differ quantitatively in their ability to build up an HO-1
response and variations inHO-1 expression dictate the pathologic
outcome of a broad range of diseases. This differential response
seems to be modulated by two polymorphisms in the HO-1 gene
promoter region. Several studies demonstrated that the ability of
a patient to respond strongly in terms of upregulating HO-1 may
be an important endogenous protective factor.
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A well described (GT)n microsatellite polymorphism in the
HO-1 promoter is thought to regulate the extension of HO-1
induction as well as its response to many stimuli. Individuals with
a lower number of (GT)n repeats retain the ability to more effi-
ciently induce HO-1 than individuals with a higher number of
repeats. Multiple studies demonstrate that individuals with fewer
repeats are less prone to certain pathologies. It is interesting to
observe that most of the pathologies affected by this polymor-
phism in humans overlap with those in which the outcome is
exacerbated by HO-1 deletion (e.g., endotoxin shock, severe sep-
sis, atherosclerosis, myocardial infarction, ischemia reperfusion
injury). Additionally, one study correlated the presence of the
shorter (GT)n polymorphism with a longer life of the individ-
ual. Individuals who lived longer were more likely to have the
“high transcriptional induction” genotype, associated with the
short HO polymorphism (Kimpara et al., 1997; Hirai et al., 2003;
Denschlag et al., 2004; Exner et al., 2004).
Studies comparing the outcome of several experimental patho-
logic conditions in HO-1−/− or wild-type mice show that when
HO-1 is lacking, the pathologic conditions studied are exacer-
bated and result in high incidence of mortality. Pharmacological
inhibition of HO activity mimics the phenotypes associated with
HO-1 deletion, while, on the other hand, induction of HO-1
or administration of its reaction products, CO and biliverdin,
is protective and usually ameliorates the pathologic conditions.
The cytoprotective effects of HO-1 and/or of its final products,
CO and biliverdin/bilirubin have been demonstrated in a variety
of diseases, including immune-mediated inflammatory diseases
(rejection of transplanted organs, autoimmune diseases, asthma,
arthritis, colitis, pancreatitis, recurrent abortions), infectious
diseases (severe malaria, sepsis, endotoxin shock), cardiovascu-
lar diseases (atherosclerosis, myocardial infarction, endothelial
dysfunction, vaso-occlusion) and ischemia-reperfusion injury
(Gozzelino et al., 2010).
Several molecules that exert a beneficial effect against dif-
ferent diseases are known to act via HO-1 induction. Some
of these synthetic compounds include sialic acid, statins and
rapamycin. In addition, several molecules produced under phys-
iologic conditions might act in a similar manner, includ-
ing the anti-inflammatory cytokine interleukin (IL)-10, some
prostaglandins, VEGF (vascular endothelial growth factor), stro-
mal cell-derived factor 1, nitric oxide (NO) and NGF (nerve
growth factor) (Gozzelino et al., 2010). The mechanisms via
which these molecules could induce the expression of HO-1
is the inhibition of Bach1 activity and the activation of tran-
scription factors that promote HO-1 transcription, such as Nrf2.
Alternatively, therapeutic induction of endogenous HO-1 might
be obtained via the delivery of non-cytotoxic amount of heme or
heme-containing proteins, the so-called preconditioning. In this
manner, the administration of hemoglobin or heme was shown
to improve survival in response to endotoxic shock (Otterbein
et al., 1995), to reduce liver and kidney injury (Nath et al., 1992)
and decrease vascular stasis (Belcher et al., 2006, 2010). Similarly,
the preconditioning of Hx−/− mice with a small dose of hemin
strongly decreases their susceptibility to acute heme overload,
thus limiting heme-mediated tissue damage (Vinchi et al., 2008).
Interestingly, a physiological paradigm of heme preconditioning
is represented by sickle cell trait, in the heterozygous form. This
mutation confers protection against severe forms of malaria due
to the low concentrations of heme in the circulation that lead
to induction of endogenous HO-1 expression and protection
against Plasmodium infection (Ferreira et al., 2011). In this condi-
tion, chronic hemolysis associated to sickle cell disease induces a
state of malaria tolerance by inducing HO-1 up-regulation, which
directly supports heme degradation and drives the generation
of anti-inflammatory and anti-oxidant metabolites. Additionally,
the ability of CO to directly bind hemoglobin and inhibit its oxi-
dation, thus avoiding heme release from oxidized hemoglobin,
has been recently shown to prevent experimental cerebral malaria,
thus highlighting a new and keymechanism ofHO-mediated pro-
tection in pathologies associated with hemoglobin/heme release
(Pamplona et al., 2007; Ferreira et al., 2008; Seixas et al., 2009).
Clinical trials based on the use of CO are currently ongoing
to evaluate the potential of CO as a therapeutic agent in humans.
CO is administered by inhalation for the treatment of pathologies
such as pulmonary arterial hypertension, post-operative ileus and
idiopathic pulmonary fibrosis (see http://www.clinicaltrials.gov
website). Alternatively, in the last decade a great effort was made
to design and study molecules able to bind and deliver CO in
biological systems, known as CO-releasing molecules (CO-RMs)
(Motterlini et al., 2005). In the next years the evaluation of the
therapeutic potential of CO via inhalation or CO-RM administra-
tion will reveal whether this way may be pursued as a therapeutic
strategy to counteract pathological outcome due to heme-driven
toxicity.
PATHOLOGICAL CONDITIONS ASSOCIATED WITH
MUTATIONS IN GENES CODING FOR HEME TRANSPORTERS
POSTERIOR COLUMN ATAXIA AND RETINITIS PIGMENTOSA (PCARP)
Recently, FLVCR1 has been reported to be the causative gene for
PCARP (OMIM: #609033) (Rajadhyaksha et al., 2010; Ishiura
et al., 2011) (Table 2). PCARP is a childhood-onset, autosomal-
recessive, neurodegenerative syndrome with the clinical features
of sensory ataxia and retinitis pigmentosa. PCARP begins in
infancy with areflexia and retinitis pigmentosa. During infancy,
night blindness, peripheral visual loss with subsequent progres-
sive constriction of the visual field and loss of central retinal
function became apparent. The sensory ataxia caused by the
degeneration of the posterior column of the spinal cord results
in a loss of proprioceptive sensation. Scoliosis, camptodactyly,
achalasia, gastrointestinal dysmothility and a sensory peripheral
neuropathy are variable features of the disease. PCARP is consid-
ered a sensory ganglionopathy causing a degeneration of central
and peripheral axons without evidence of primary demyelination
(Higgins et al., 1997).
Four different homozygous mutations in FLVCR1 gene have
been reported to date. Interestingly, three of these mutations
(c.361A>G, c.574T>C, and c.721G>A) (Rajadhyaksha et al.,
2010) occur in the first exon of FLVCR1 gene, thus probably
affecting only FLVCR1a. However, we cannot exclude the possi-
bility that these mutations could interfere with any still unknown
regulatory sequences important for FLVCR1b expression. The
other mutation (c1477G>C) (Ishiura et al., 2011) is in the tenth
exon of FLVCR1 gene, common to both Flvcr1a and Flvcr1b
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transcripts (Chiabrando et al., 2012), thus probably affecting
both transporters. Each mutation corresponds to a specific
aminoacid substitution (Asn121Asp, Cys192Arg, Ala241Thr, and
Gly493Arg) within putative transmembrane domains of FLVCR1:
1, 3, 5, and 12 transmembrane domains, respectively. Yanatori
et al. (2012) investigated the consequences of the reported
FLVCR1 mutations on the plasma membrane heme exporter
FLVCR1a. In vitro studies indicate that all the four identified
mutations affect the subcellular localization, half-life and heme-
export function of FLVCR1a (Yanatori et al., 2012). However, the
consequences of all these mutations on the expression, localiza-
tion and activity of FLVCR1b have not been investigated yet. It
has been proposed that the mutant FLVCR1a proteins fail to fold
properly in the endoplasmic reticulum and are rapidly degraded
in the lysosomes; loss of FLVCR1a could lead to heme overload,
oxidative stress and apoptosis of photoreceptors in the retina and
sensory neurons in the posterior column of the spinal cord of
PCARP patients (Yanatori et al., 2012). Actually, this is merely a
hypothesis and evidences of heme overload, heme-induced tox-
icity, and apoptosis in PCARP patients or mouse models of the
disease are still lacking. Of note, apoptosis is the final and com-
mon cause of photoreceptors degeneration in several forms of
retinitis pigmentosa (Marigo, 2007).
The reason why the loss of FLVCR1a could affect two spe-
cific sensory modalities, vision and proprioception, is unknown.
The expression levels of Flvcr1 mRNA have been confirmed in
the mouse brain (neocortex, striatum, hippocampus, and cere-
bellum), posterior column of the spinal cord, retina and retinal
pigment epithelium. The highest levels of Flvcr1mRNA have been
found in the retina and spinal cord thus suggesting a correlation
between the regional specificity of Flvcr1 mRNA expression and
the selective degenerative pathology of PCARP (Rajadhyaksha
et al., 2010; Gnana-Prakasam et al., 2011). However, FLVCR1 is
ubiquitously expressed (Quigley et al., 2004; Chiabrando et al.,
2012) and the observation that mutations in the FLVCR1 gene
cause sensory ataxia and retinitis pigmentosa was completely
unexpected. Two different mouse models of FLVCR1 deficiency
have been generated; in both cases, the loss of specific FLVCR1
isoforms severely affects embryonic development (Keel et al.,
2008; Chiabrando et al., 2012), a stronger phenotype compared
to that of PCARP patients. Furthermore, the mouse models of
Flvcr1 deficiency suggest an essential role of FLVCR1 isoforms
in erythroid differentiation and in the maintenance of endothe-
lial integrity (Keel et al., 2008; Chiabrando et al., 2012). PCARP
patients did not suffer from anemia (Rajadhyaksha et al., 2010;
Yanatori et al., 2012). On the other hand, neurological defects
have not been reported in mouse models of Flvcr1 deficiency. The
reasons of the discrepancies between the human disease and the
mouse models need to be further investigated.
Further work is needed to understand how the loss of a ubiq-
uitously expressed heme exporter could lead to the selective
pathological features of PCARP.
DIAMOND BLACKFAN ANEMIA (DBA)
A role for FLVCR1 in the pathogenesis of Diamond Blackfan
Anemia (DBA; OMIM: #105650) has been proposed due to the
observation that the feline leukemia virus subgroup C causes a
pure cell aplasia in cats by interfering with the expression of
FLVCR1 and that mice lacking both FLVCR1 isoforms phenocopy
the human disease (Tailor et al., 1999; Quigley et al., 2000; Keel
et al., 2008).
DBA is an autosomal dominant disorder with incomplete pen-
etrance due to mutations in several genes coding for ribosomal
proteins; the most common mutation is in ribosomal protein
S19 gene (RPS19) (Campagnoli et al., 2008). DBA patients are
characterized by a severe block of erythroid differentiation at the
proerythroblast stage associated to congenital malformations and
cancer predisposition (Flygare and Karlsson, 2007; Chiabrando
and Tolosano, 2010; Narla and Ebert, 2010). Accordingly, FLVCR1
deficient mice are characterized by a block of erythroid differen-
tiation as well as growth defects (Keel et al., 2008).
Mutations in FLVCR1 gene have not been identified in DBA
patients (Quigley et al., 2005). Rey et al. (2008) identified sev-
eral alternatively spliced Flvcr1 transcripts, encoding proteins
with aberrant expression and function. Due to the experi-
mental strategy, only Flvcr1a transcript was evaluated in this
work. Interestingly, the aberrant alternative splicing of Flvcr1a is
increased in immature erythroid cells of some DBA patients neg-
ative for RPS19 mutations, while the expression of the wild-type
protein is decreased (Rey et al., 2008). The molecular mechanism
leading to the aberrant alternative splicing of Flvcr1a in DBA is
unknown. These data suggest that decreased FLVCR1a expres-
sion and alteration of heme metabolism could contribute to the
pathogenesis of DBA.
The identification of FLVCR1b essential role in heme syn-
thesis and erythroid differentiation, leads to the hypothesis that
alteration of FLVCR1b expression could also concur to the patho-
genesis of DBA (Chiabrando et al., 2012). Whether aberrant alter-
native splicing of Flvcr1b transcript also occurs in DBA immature
erythroid cells, still needs to be addressed.
Mouse models of Flvcr1 deficiency are also characterized by
defective growth (Keel et al., 2008) and skeletal malformations
(Chiabrando et al., 2012). Thus, FLVCR1a could also have a role
in the development of the congenital malformations observed in
DBA patients.
Although FLVCR1 is far to be the causative gene for DBA, we
could speculate that the aberrant expression of FLVCR1 isoforms
could contribute to different pathological features of DBA.
Considering the essential role of FLVCR1 isoforms during
erythroid differentiation, it will be interesting to analyze their
expression also in other erythroid diseases. An alteration of the
expression of FLVCR1 isoforms may play a role in the pathogene-
sis of disorders characterized by an imbalance between heme and
globin synthesis too.
PUTATIVE ROLE OF FLVCR1 IN DRUG METABOLISM
The recent finding that liver conditional Flvcr1a−/− mice show
a reduced expression and activity of cytochromes P450 sug-
gests that heme export may have an impact on cytochrome
function. About 50% of hepatic heme is used for synthesis of
P450 enzymes, which metabolize exogenous and endogenous
compounds, including hormones, xenobiotics, drugs, and car-
cinogens. It is well-known that a reduction in heme availability
due to an enhanced heme degradation leads to the impairment
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of cytochrome function (Correia et al., 2011). On the other
hand, the lack of FLVCR1a-mediated heme export in hepato-
cytes, although leading to an increase in the cytosolic heme
pool, similarly causes a reduction in cytochrome activity. In
hepatocytes, heme is likely formed in excess over its metabolic
needs and heme homeostasis is ensured by a combination of
synthetic, degradative, and export mechanisms. FLVCR1a, by
exporting heme excess out of the cell, controls the size of the
cytosolic heme pool, thus allowing proper heme synthesis and
new cytochrome formation. FLVCR1a loss causes heme synthe-
sis inhibition, due to the expansion of the cytosolic heme pool,
ultimately leading to a decrease in cytochrome function (Vinchi
et al., 2014). These observations have potential implications
for hepatic metabolism of xenobiotics and drugs. In particular,
deletion or mutations in Flvcr1a and other pathologic condi-
tions that reduce its expression potentially cause a reduction in
cytochrome activity, thus altering drug metabolism. Therefore,
individuals that routinely assume drugs for therapeutic purposes
may show a reduced ability to induce cytochromes P450 and to
metabolize pharmaceuticals, thus being more susceptible to drug
intoxication. In the near future, the mouse model of FLVCR1a
deletion in hepatocytes could be applied for metabolic studies
to address the importance of hepatic heme export upon drug
administration.
HYPERURICAEMIA AND GOUT
As stated above, ABCG2 was initially shown to transport a wide
range of substrates including drugs, xenobiotics, foodmetabolites
and heme. Only recently, genetic studies in humans have iden-
tified urate as a physiological substrate of ABCG2, perhaps the
most relevant. Indeed, a genome-wide association study identi-
fied common alleles in ABCG2 as associated with serum urate
level and risk of gout (OMIM: #138900) (Table 2) (Dehghan
et al., 2008). ABCG2 expression in the apical membrane of
human proximal tubule cells (Doyle and Ross, 2003), the main
site of urate handling in the kidney, is consistent with a role for
ABCG2 in urate excretion. Gout is a common form of inflam-
matory arthritis and occurs when uric acid crystallizes in the
form of monosodium urate, precipitating in joints, on tendons,
and in the surrounding tissues. These crystals then trigger a
local immune-mediated inflammatory reaction. Genetic studies
identified a SNP in the exon 5 of ABCG2 gene that leads to a
glutamine-to-lysine amino acid substitution (Q141K) (Dehghan
et al., 2008). The Q141K variant has been shown to have a sig-
nificant reduced capacity to transport urate and, when expressed
in mammalian cells, Q141K ABCG2 expression is significantly
lower than that of wild-type protein (Imai et al., 2002; Mizuarai
et al., 2004; Morisaki et al., 2005;Woodward et al., 2009). Another
study on the Japanese population identified a different vari-
ant as associated to hyperuricemia and gout (Yamagishi et al.,
2010).
Many additional SNPs in ABCG2 gene have been identi-
fied and associated to altered drug resistance (Woodward et al.,
2011). Future studies will have to address whether additional
SNPs also affect serum urate concentration in human. Finally,
how these polymorphisms affect heme transport remains to be
determined.
FOWLER SYNDROME
Mutations in the FLVCR2 gene have been associated to the Fowler
syndrome (OMIM: #225790) (Table 2), a rare lethal autosomal-
recessive disorder of brain angiogenesis, first described in
1972 (Fowler et al., 1972). The Fowler syndrome is a cere-
bral proliferative glomeruloid vasculopathy resulting in abnor-
mally thickened and aberrant perforating vessels, forming
glomeruloid structures throughout the central nervous sys-
tem. These defects lead to hydranencephaly and hydrocephaly
and are restricted to the central nervous system parenchyme.
In addition to cerebral proliferative glomeruloid vasculopa-
thy, fetuses affected by the Fowler syndrome also show limb
deformities.
Several kinds of mutations were identified in cases of Fowler
syndrome (Meyer et al., 2010; Thomas et al., 2010), but it is
not clear how these mutations could affect FLVCR2 expression,
functions or localization.
The mechanism by which FLVCR2 mutations could lead to
abnormal angiogenesis is also unknown. Some hypotheses have
been put forward.
First, it has been postulated that the role of FLVCR2 in calcium
trafficking, proposed by Brasier et al. (2004), could explain its
involvement in Fowler syndrome. Indeed, the altered angiogene-
sis in Fowler syndrome has been supposed to be due to a deficit in
pericytes, cells essential for capillary stabilization and remodeling
during brain angiogenesis (Thomas et al., 2010). These cells inter-
act with endothelial cells, whose proliferation and motility are
calcium-dependent events. Moreover, the Fowler syndrome has
been associated with varying degrees of calcification throughout
the central nervous system (Harding et al., 1995).
Although possible, this hypothesis seems to be inadequate
because the involvement of FLVCR2 in calcium transport has not
been demonstrated. Moreover, it is not clear whether the effects
on pericytes observed in fetuses affected by Fowler syndrome is
the primary cause or an effect of the disease.
A second hypothesis to explain FLVCR2 implication in
the Fowler syndrome is based on its heme import activity.
It has been observed in some cases of Fowler syndrome
that there is a deficiency in the heme-dependent complexes
IV of the mitochondrial electron transport chain, essen-
tial for the production of adenosine triphosphate by oxida-
tive phosphorylation. Since young neurons that migrate to
the neocortex are dependent on oxidative phosphorylation,
it has been speculated that Flvcr2 disruption could lead to
dysfunction of the mitochondrial electron transport chain,
thus causing the neurodegeneration and the developmen-
tal abnormalities found in Fowler syndrome (Duffy et al.,
2010).
Finally, a third hypothesis is that alteration on FLVCR2 heme-
import activity could account for cellular iron overload, a con-
dition known to be associated to neurodegeneration and bone
abnormalities (Duffy et al., 2010).
Although all conceivable, the three hypotheses need exper-
imental verification and it remains unclear why the damaged
areas in Fowler syndrome are restricted to the central nervous
system and whether the proliferative vasculopathy is primary or
secondary to the neurodegeneration.
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HEREDITARY FOLATE MALABSORPTION SYNDROME
The only known disorder associated to mutations in the
HCP1/PCFT gene relates to its role in the transport of folates,
while the effects of the loss of its heme-import functions seem to
be negligible, suggesting the instauration of alternative compen-
satory mechanisms to support cellular heme-iron uptake in the
absence of HCP1/PCFT.
Mutations in the HCP1/PCFT gene have been associated to
the hereditary folate malabsorption syndrome (HFM; OMIM:
#229050), a rare autosomal recessive disorder first described in
1961 (Luhby et al., 1961) (Table 2).
Folates are essential cofactors required for key epigenetic and
biosynthetic processes, such as de novo synthesis of purines and
pyrimidines, methionine and deoxythymidylate monophosphate.
Mammals do not synthesize folates, and body needs are met by
duodenal and jejunal absorption of folates contained in the diet.
The basis for HFM is the impaired intestinal folate absorp-
tion, resulting in severe systemic and cerebrospinal fluid folate
deficiency in a few months after birth.
Patients affected by HFM show anemia, diarrhea, pancytope-
nia, hypoimmunoglobulinemia, and frequent neurological dys-
functions like developmental delays, cognitive impairment, and
epilepsy. Many kinds of mutations have been reported (Qiu et al.,
2006; Zhao et al., 2007; Shin et al., 2011; Diop-Bove et al., 2013),
occurring in different sites ofHCP1/PCFT gene and with different
effects on the protein encoded by the mutated alleles.
If untreated, the disease is fatal and, if treatment is delayed,
the neurologic deficits can become permanent. Normalization
of blood, and rarely cerebrospinal fluid, folate level could be
achieved by administration of low doses of parenteral folates or
of pharmacological doses of oral folates. In the latter case, folates
are probably absorbed by the bidirectional Reduced Folate Carrier
1 (RFC1), a folate importer alternative to HCP1/PCFT, which is
expressed in the upper small intestine. RFC1 shows a lower affin-
ity for folates as compared with HCP1/PCFT, but can compensate
for HCP1/PCFT loss in HFM patients treated with high doses of
folates (Qiu et al., 2006; Zhao et al., 2007).
The Hcp1/Pcft−/− mouse represents the murine model for
this HFM syndrome (Salojin et al., 2011) (Table 1).Hcp1/Pcft−/−
mice die by 10–12 weeks of age and show a haematological profile
which closely resembles that observed in human HFM patients.
CONCLUDING REMARKS
The excess of free-heme is toxic due to its high reactivity and its
ability to promote oxidative stress on lipids, proteins and nucleic
acids, eventually leading to cell death.
The existence of multiple levels of heme control indicates that
mammals specifically evolved systems able to limit heme amount
outside and inside the cell to counteract heme potential toxicity.
As a primary defence mechanism, Hx scavenges free circu-
lating heme, thereby avoiding it to exert its pro-oxidant effects.
Indeed, Hx saturation observed in hemolytic disorders leads to
heme-driven tissue damage and oxidative stress.
The control of heme synthesis and degradation has a key role
in the regulation of intracellular heme levels and these two mech-
anisms are respectively inhibited and induced by heme itself.
Alterations in these processes lead to pathological iron or heme
accumulation. Mutations in ALAS2 gene cause insufficient heme
production, mitochondria iron overload, and oxidative stress, as
observed in sideroblastic anemia (Sheftel et al., 2009). HO-1 defi-
ciency leads as well to anemia and inability to efficiently reuse
tissue heme-iron. Moreover, HO-1 has a cytoprotective action
that resides not only in the degradation of toxic heme but also in
the production of the antioxidant molecules CO and biliverdin.
The recent identification of plasma membrane heme trans-
porters suggests that intracellular heme amount could be reg-
ulated not only at the level of its synthesis and catabolism but
also at the level of heme export and import. Nevertheless, apart
FLVCR1 for which studies in mouse models have provided com-
pelling evidence that it exerts a physiologic role as a heme
exporter, the experimental evidence that ABCG2, FLVCR2, and
HCP1/PCFT are heme transporter with a physiologic role in
heme/iron homeostasis are very poor. Thus, it would bemore cor-
rect to refer to these molecules as secondary regulators of heme
and/or porphyrin metabolism. This conclusion is corroborated
by genetic studies in humans that failed in finding a clear associ-
ation between mutations in genes coding for heme transporters
and disorders of heme metabolism as was expected from studies
on cellular and animal models. Mutations in FLVCR1 or FLVCR2
affect specific cell populations, sensory neurons and photorecep-
tors or vascular cells of the central nervous system, respectively.
Polimorphisms in ABCG2 result in defective urate excretion while
mutations in HCP1/PCFT cause folate malabsorption. These dis-
crepancies may be related to the different kind of mutations taken
into considerations, loss-of-functionmutations inmice and point
mutations resulting in proteins with altered function/localization
in humans. It is possible that null mutations can affect heme
metabolism also in humans or that specific polimorphisms in
genes coding for heme transporters can differentially alter the
import/export of specific substrates. The full comprehension of
the role of FLVCR1-mediated heme export in human physiology
and pathology is a challenge for future studies as well as the defi-
nition of the role of FLVCR2, ABCG2, and HCP1/PCFT in heme
metabolism. Of course, the definition of protein structure and
the identification of residues critical for heme transport in heme
transporters are very important issues. In addition, the descrip-
tion of the regulation of these transporters in different tissues and
following different stimuli will be of relevance to fully understand
the multi-level system of heme control.
In the future, the comprehension of these mechanisms
could have important clinical implications. Targeting heme
transporters could be therapeutically useful to prevent heme-
driven tissue damage in pathologies characterized by enhanced
oxidative-stress.
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